Improvement of motor nerve conduction velocity in diabetic rats requires normalization of the polyol pathway metabolites flux

Journal of Pharmacological Sciences

Volumn 109, Issue 2, 2009, Pages 203-210

  Matsumoto, Takafumi ^a   Ono, Yoshiyuki ^a   Kurono, Masuo ^a   Kuromiya, Akemi ^a   Nakamura, Keiji ^b   Bril, Vera ^c  

^a DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

^b Analytical Chemistry Center Nichiei Sangyo Co Ltd   (Japan)

^c TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

Aldose reductase inhibitor; Fructose; Motor nerve conduction velocity (MNCV); Ranirestat; Sorbitol

Indexed keywords

ALDEHYDE REDUCTASE; FRUCTOSE; GLUCOSE; POLYOL; RANIRESTAT; SORBITOL; STREPTOZOCIN; ZENARESTAT; PYRAZINE DERIVATIVE; SPIRO COMPOUND; SX 3030;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG STRUCTURE; GLUCOSE BLOOD LEVEL; IC 50; MALE; MOTOR NERVE CONDUCTION; NONHUMAN; RAT; SCIATIC NERVE; STREPTOZOCIN DIABETES; ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; ERYTHROCYTE; EXPERIMENTAL DIABETES MELLITUS; IN VITRO STUDY; METABOLISM; NERVE CONDUCTION; PATHOPHYSIOLOGY; WISTAR RAT;

ALDEHYDE REDUCTASE; ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; ERYTHROCYTES; FRUCTOSE; MALE; NEURAL CONDUCTION; PYRAZINES; RATS; RATS, WISTAR; SCIATIC NERVE; SORBITOL; SPIRO COMPOUNDS;

EID: 65449133947     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.08177FP     Document Type: Article

References (23)

1. Obrosova IG, Ilnytska O, Lyzogubov VV, Pavlov IA, Mashtalir N, Nadler JL, et al. High-fat diet induced neuropathy of prediabetes and obesity: effects of "healthy" diet and aldose reductase inhibition. Diabetes. 2007;56:2598-2608.
2. Yagihashi S. Diabetic neuropathy. Nippon Rinsho. 2006;28 Suppl 3:155-160.
3. Baba M, Kimura K, Suda T, Yagihashi S. Aomori Diabetic Study (ADNS) Group. Three-year inhibition of aldose reductase on development of symptomatic neuropathy in diabetic patients. J Peripher Nerv Syst. 2006;11:176-178.
4. Lorenzi M. The polyol pathway as a mechanism for diabetic retinopathy: attractive, elusive, and resilient. Exp Diabetes Res. 2007;2007:61038.
5. Takamura Y, Tomomatsu T, Kubo E, Tsuzuki S, Akagi Y. Role of the polyol pathway in high glucose-induced apoptosis of retinal pericytes and proliferation of endothelial cells. Invest Ophthalmol Vis Sci. 2008;49:3216-3223.
6. Schrijvers BF, De Vriese AS. Novel insights in the treatment of diabetic nephropathy. Acta Clin Belg. 2007;62:278-290.
7. Cameron NE, Cotter MA, Hohman TC. Interactions between essential fatty acid, prostanoid, polyol pathway and nitric oxide mechanisms in the neurovascular deficit of diabetic rats. Diabetologia. 1996;39:172-182.
8. Cappiello M, Vilardo PG, Micheli V, Jacomelli G, Banditelli S, Leverenz V, et al. Thiol disulfide exchange modulates the activity of aldose reductase in intact bovine lens as a response to oxidative stress. Exp Eye Res. 2000;70:795-803.
9. Oates PJ. Aldose reductase, still a compelling target for diabetic neuropathy. Curr Drug Targets. 2008;9:14-36.
10. Matsumoto T, Ono Y, Kurono M, Kuromiya A, Nakamura K, Bril V. Ranirestat (AS-3201), a potent aldose reductase inhibitor, reduces sorbitol levels and improves motor nerve conduction velocity in streptozotocin-diabetic rats. J Pharmacol Sci. 2008; 107:231-237.
11. Matsumoto T, Ono Y, Kuromiya A, Toyosawa K, Ueda Y, Bril V. Long-term treatment with ranirestat (AS-3201), a potent aldose reductase inhibitor, suppresses diabetic neuropathy and cataract formation in rats. J Pharmacol Sci. 2008;107:340-348.
12. Kurono M, Fujiwara I, Yoshida K. Stereospecific interaction of a novel spirosuccinimide type aldose reductase inhibitor, AS- 3201, with aldose reductase. Biochemistry. 2001;27:8216-8226.
13. Sima AA, Bril V, Nathaniel V, McEwen TA, Brown MB, Lattimer SA, et al. Regeneration and repair of myelinated fibers in sural-nerve biopsy specimens from patients with diabetic neuropathy treated with sorbinil. N Engl J Med. 1988;319:548-555. (Pubitemid 18215833)
14. Wrobel J, Millen J, Sredy J, Dietrich A, Kelly JM, Gorham BJ, et al. Orally active aldose reductase inhibitors derived from bioisosteric substitutions on tolrestat. J Med Chem. 1989;32: 2493-2500. (Pubitemid 19269979)
15. Calcutt NA, McMurray HF, Moorhouse DF, Bache M, Parthasarathy S, Powell HC, et al. Inhibition of macrophage chemotaxis and peripheral nerve regeneration in normal and hyperglycemic rats by the aldose reductase inhibitor Tolrestat. Exp Neurol. 1994;128:226-232. (Pubitemid 24376951)
16. Greene DA, Arezzo JC, Brown MB. Effect of aldose reductase inhibition on nerve conduction and morphometry in diabetic neuropathy. Zenarestat Study Group. Neurology. 1999;53:580-591. (Pubitemid 29382055)
17. Greene DA, Stevens MJ, Feldman EL. Diabetic neuropathy: scope of the syndrome. Am J Med. 1999;107:2S-8S. (Pubitemid 8230324)
18. Hotta N, Toyota T, Matsuoka K, Shigeta Y, Kikkawa R, Kaneko T, et al. Clinical efficacy of fidarestat, a novel aldose reductase inhibitor, for diabetic peripheral neuropathy: a 52- week multicenter placebo-controlled double-blind parallel group study. Diabetes Care. 2001;24:1776-1782.
19. Bril V, Buchanan RA. Aldose reductase inhibition by AS-3201 in sural nerve from patients with diabetic sensorimotor polyneuropathy. Diabetes Care. 2004;27:2369-2375.
20. Pfeifer MA, Schumer MP, Gelber DA. Aldose reductase inhibitors: the end of an era or the need for different trial designs? Diabetes. 1997;46 Suppl 2:S82-S89. (Pubitemid 27377404)
21. Perkins BA, Bril V. Emerging therapies for diabetic neuropathy: a clinical overview. Curr Diabetes Rev. 2005;1:271-280.
22. Bril V, Buchanan RA. Long-term effects of ranirestat (AS-3201) on peripheral nerve function in patients with diabetic sensori- motor polyneuropathy. Diabetes Care. 2006;29:68-72.
23. Mizuno K, Kato N, Makino M, Suzuki T, Shindo M. Continuous inhibition of excessive polyol pathway flux in peripheral nerves by aldose reductase inhibitor fidarestat leads to improvement of diabetic neuropathy. J Diabetes Complications. 1999;13:141-150.